文献速递胸部肿瘤

达可替尼对比吉非替尼改善EGFR突变晚期NSCLC总生存

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
PubMed 文献 · J Clin Oncol · 2018-06-04

ARCHER 1050是一项随机、开放标签、III期研究,比较达可替尼与吉非替尼一线治疗EGFR激活突变晚期NSCLC的疗效。最终总生存分析显示,达可替尼组中位OS为34.1个月,吉非替尼组为26.8个月,风险比0.760(95%CI 0.582-0.993;

要点

  • 30个月OS率分别为56.2%和46.3%。
  • 达可替尼应被视为此类患者的标准治疗选择之一。

核心结论

  • 在EGFR激活突变晚期NSCLC患者中,达可替尼是首个在III期随机研究中较标准治疗TKI显著改善OS的第二代EGFR-TKI。

研究设计与样本

  • ARCHER 1050为随机、开放标签、III期研究,纳入治疗初治的EGFR激活突变(19外显子缺失或21外显子L858R)晚期NSCLC患者,按1:1随机分配至达可替尼组(n=227)或吉非替尼组(n=225)。

主要发现

  • 中位随访31.3个月,达可替尼组死亡103例(45.4%),吉非替尼组死亡117例(52.0%)。
  • 达可替尼组中位OS为34.1个月,吉非替尼组为26.8个月。
  • 30个月OS概率分别为56.2%和46.3%。
  • 基于基线特征的初步亚组分析结果与主要OS分析一致。

临床怎么用

  • 对于EGFR激活突变的晚期NSCLC患者,达可替尼应被视为标准治疗选择之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progression-free survival with dacomitinib. The mature overall survival (OS) analysis for the intention-to-treat population is presented here. Patients and Methods In this multinational, multicenter study, patients age 18 years or older (≥ 20 years in Japan and Korea) who had an Eastern Cooperative Oncology Group performance status of 0 or 1 and newly diagnosed NSCLC with activating mutations in EGFR (exon 19 deletion or exon 21 L858R) were enrolled and randomly assigned in a 1:1 manner to dacomitinib (n = 227) or gefitinib (n = 225). Random assignment was stratified by race (Japanese, Chinese, other East Asian, or non-Asian) and EGFR mutation type. The final OS analysis was conducted with a data cutoff date of February 17, 2017; at that time 220 deaths (48.7%) were observed. Results During a median follow-up time of 31.3 months, 103 (45.4%) and 117 (52.0%) deaths occurred in the dacomitinib and gefitinib arms, respectively. The estimated hazard ratio for OS was 0.760 (95% CI, 0.582 to 0.993; two-sided P = .044). The median OS was 34.1 months with dacomitinib versus 26.8 months with gefitinib. The OS probabilities at 30 months were 56.2% and 46.3% with dacomitinib and gefitinib, respectively. Preliminary subgroup analyses for OS that are based on baseline characteristics were consistent with the primary OS analysis. Conclusion In patients with advanced NSCLC and EGFR activating mutations, dacomitinib is the first second-generation epidermal growth factor receptor tyrosine kinase inhibitor (TKI) to show significant improvement in OS in a phase III randomized study compared with a standard-of-care TKI. Dacomitinib should be considered one of the standard treatment options for these patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mok TS, Cheng Y, Zhou X, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018. PMID: 29864379. doi:10.1200/JCO.2018.78.7994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。